The REFLECT Statement: Reporting Guidelines for Randomized Controlled Trials in Livestock and Food Safety: Explanation and Elaboration by Sargeant, Jan M. et al.
Veterinary Diagnostic and Production Animal
Medicine Publications
Veterinary Diagnostic and Production Animal
Medicine
2010
The REFLECT Statement: Reporting Guidelines
for Randomized Controlled Trials in Livestock and
Food Safety: Explanation and Elaboration
Jan M. Sargeant
University of Guelph
Annette M. O'Connor
Iowa State University, oconnor@iastate.edu
Ian A. Gardner
University of California - Davis
James S. Dickson
Iowa State University, jdickson@iastate.edu
Mary E. Torrence
United States Department of Agriculture
See next page for additional authors
Follow this and additional works at: https://lib.dr.iastate.edu/vdpam_pubs
Part of the Animal Sciences Commons, Large or Food Animal and Equine Medicine Commons,
and the Veterinary Preventive Medicine, Epidemiology, and Public Health Commons
The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/
vdpam_pubs/5. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Veterinary Diagnostic and Production Animal Medicine at Iowa State University Digital
Repository. It has been accepted for inclusion in Veterinary Diagnostic and Production Animal Medicine Publications by an authorized administrator
of Iowa State University Digital Repository. For more information, please contact digirep@iastate.edu.
The REFLECT Statement: Reporting Guidelines for Randomized
Controlled Trials in Livestock and Food Safety: Explanation and
Elaboration
Abstract
Concerns about the completeness and accuracy of reporting of randomized clinical trials (RCTs) and the
impact of poor reporting on decision-making have been documented in the medical field over the past several
decades. Experience from RCTs in human medicine would suggest that failure to report critical trial features
can be associated with biased estimated effect measures, and there is evidence to suggest similar biases occur
in RCTs conducted in livestock populations. In response to these concerns, standardized guidelines for
reporting RCTs were developed and implemented in human medicine. The Consolidated Standards of
Reporting Trials (CONSORT) statement was first published in 1996 with a revised edition published in
2001. The CONSORT statement consists of a 22-item checklist for reporting a RCT and a flow diagram to
follow the number of participants at each stage of a trial. An explanation and elaboration document not only
defines and discusses the importance of each of the items, but also provides examples of how this information
could be supplied in a publication. Differences between human and livestock populations necessitate
modifications to the CONSORT statement to maximize its usefulness for RCTs involving livestock. These
have been addressed in an extension of the CONSORT statement titled the REFLECT statement: Methods
and processes of creating reporting guidelines for randomized control trials for livestock and food safety. The
modifications made for livestock trials specifically addressed the common use of group housing and group
allocation to intervention in livestock studies, the use of a deliberate challenge model in some trials, and
common use of non-clinical outcomes, such as contamination with a foodborne pathogen. In addition, the
REFLECT statement for RCTs in livestock populations proposed specific terms or further clarified terms as
they pertained to livestock studies.
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ABSTRACT
Concerns about the completeness and accuracy of reporting of randomized clinical trials (RCTs) and the impact of poor
reporting on decision-making have been documented in the medical field over the past several decades. Experience from RCTs in
human medicine would suggest that failure to report critical trial features can be associated with biased estimated effect measures,
and there is evidence to suggest similar biases occur in RCTs conducted in livestock populations. In response to these concerns,
standardized guidelines for reporting RCTs were developed and implemented in human medicine. The Consolidated Standards of
Reporting Trials (CONSORT) statement was first published in 1996 with a revised edition published in 2001. The CONSORT
statement consists of a 22-item checklist for reporting a RCT and a flow diagram to follow the number of participants at each
stage of a trial. An explanation and elaboration document not only defines and discusses the importance of each of the items, but
also provides examples of how this information could be supplied in a publication. Differences between human and livestock
populations necessitate modifications to the CONSORT statement to maximize its usefulness for RCTs involving livestock.
These have been addressed in an extension of the CONSORT statement titled the REFLECT statement: Methods and processes of
creating reporting guidelines for randomized control trials for livestock and food safety. The modifications made for livestock
trials specifically addressed the common use of group housing and group allocation to intervention in livestock studies, the use of
a deliberate challenge model in some trials, and common use of non-clinical outcomes, such as contamination with a foodborne
pathogen. In addition, the REFLECT statement for RCTs in livestock populations proposed specific terms or further clarified
terms as they pertained to livestock studies.
The randomized clinical trial is a very beautiful technique, of
wide applicability, but as with everything else, there are snags.
When humans have to make observations, there is always the
possibility of bias (20).
The randomized controlled trial (RCT) is the gold
standard for evaluating the efficacy of therapeutic and preven-
tive interventions. In livestock populations, RCTs can be used
to evaluate the efficacy of interventions related to animal health
and productivity, as well as food-safety outcomes. However,
trials that do not employ sound methodologies are associated
with biased-effect estimates (52, 61, 93). Biased trial results
have the potential to mislead decision making by clinicians,
researchers, and policy-makers, which ultimately impacts
livestock producers and the general public. The reader of a
published clinical trial cannot know the exact methods used to
conduct the trial, since the only information available is
provided in the publication. Therefore, it is essential that
authors of clinical trials provide in the publication complete
and accurate details of the methods used.
INCOMPLETE AND INACCURATE REPORTING IN
PUBLISHED LIVESTOCK INTERVENTION TRIALS
The basic criteria essential to the validity of RCTs have
been reviewed in the veterinary literature (29, 58, 85).
* Author for correspondence. Tel: 519-824-4120, Ext 54045; Fax:
519-766-1730; E-mail: sargeanj@uoguelph.ca.
Note: The REFLECT Explanation and Elaboration Document is
published in the Journal of Food Protection and Zoonoses and Public
Health. The methods and processes for creating the REFLECT statement
are published in Journal of Food Protection, Journal of Veterinary Internal
Medicine, Zoonoses and Public Health, Preventive Veterinary Medicine,
and Journal of Swine Health and Production. Authors may use any one of
these references when citing REFLECT. These materials are available at the
REFLECT statement Web site, www.reflect-statement.org.
579
Journal of Food Protection, Vol. 73, No. 3, 2010, Pages 579–603
However, despite the availability of these criteria, the
quality of reporting of intervention trials remains poor. An
assessment of the quality of RCTs published in one journal
revealed that, although some of the trials provided informa-
tion on methodological features, many others failed to do so
(33). These trials lacked information related to the method
of treatment allocation, the grouping of animals relative to
treatment allocation, the use or non-use of blinding, and the
method of statistical analysis (33). Further, several system-
atic reviews in pre-harvest food safety (24, 70) and animal
health (14, 76, 112) have noted a lack of reporting of group
allocation methods, blinding, and details related to inter-
vention protocols, outcome assessments, and statistical
analysis methods in some published clinical trials. This
lack of consistency in reporting makes it almost impossible
to summarize sufficient data appropriately, thereby affecting
the ability to arrive at an overall conclusion on a particular
intervention or outcome. For example, in 100 randomly
selected trials with animal health or production outcomes,
only 67% reported random allocation to intervention group,
35% clearly described the number of animals housed
together in a group, 4% reported the use of double blinding
where blinding was feasible, and 62% reported the number
of study units lost to follow-up during the trial (89). In an
evaluation of 100 pre-harvest food-safety trials, randomiza-
tion, double blinding, and the number of subjects lost to
follow-up were reported in 46%, 0%, and 43% of trials,
respectively, and the number of animals housed together
was stated in 52% of the trials (91).
Experience gained from RCTs in human medicine would
suggest that failure to report critical trial features can be
associated with biased estimates of effect measures, and there
is evidence to suggest that similar biases occur in RCTs
conducted in livestock populations. A systematic review of
trials evaluating the efficacy of vaccination for the treatment
of pinkeye in cattle found that trials not reporting random
allocation to intervention group and blinding were more likely
to conclude that the vaccine was efficacious than trials where
these features were reported (14). Similarly, evaluations of
100 randomly selected trials with animal health or production
outcomes and 100 randomly selected trials with food-safety
outcomes revealed significant associations between the
proportion of positive treatment effects within trials and
failure to report trial features, such as random allocation to
intervention group, exclusion criteria for study subjects,
details of the intervention protocol, animal signalment, and
details of the measurement of all outcomes (89, 91).
IMPROVING THE REPORTING OF RCTS IN THE
MEDICAL LITERATURE: THE CONSORT
STATEMENT
Concerns about the completeness and accuracy of
reporting of RCTs have been documented in the medical field
over the past several decades (1, 25, 44, 84, 93, 101). In
response to these concerns, standardized guidelines for
reporting RCTs were developed and have been implemented.
The Consolidated Standards of Reporting Trials (CONSORT)
statement was first published in 1996 (8). A revised version
was simultaneously published by four leading medical journals
in 2001 (62–65). The CONSORT statement consists of a 22-
item checklist for reporting an RCT and a flow diagram to
follow the number of participants at each stage of a trial. The
items for the checklist were selected because there was
empirical evidence in the literature indicating the potential for
biased estimates of treatment effects when these items were not
reported, or because the information was deemed essential to
evaluate the reliability or relevance of the findings (61). An
explanation and elaboration document defines and discusses
the importance of each of the items, in addition to providing
examples of how this information could be provided
in a publication (5). The CONSORT statement document
currently is endorsed by several hundred journals (www.
consort-statement.org), including two veterinary journals: the
Equine Veterinary Journal and The Veterinary Journal (47).
Evaluations of RCTs since implementation of the CONSORT
statement suggest that the statement has improved the
quality of reporting of RCTs (53, 60, 83). Extensions of the
CONSORT statement have been developed for cluster trials
(16–18), harms (49), herbals interventions (38–41), nonphar-
macological interventions (10), and abstracts (48).
MODIFICATIONS TO THE CONSORT STATEMENT
FOR USE IN TRIALS INVOLVING LIVESTOCK
SPECIES
Differences between human and livestock populations
necessitate modifications to the CONSORT statement to
maximize its usefulness for RCTs involving livestock. These
have been addressed in an extension of the CONSORT
statement titled the ‘‘REFLECT’’ statement—‘‘The RE-
FLECT statement: methods and processes of creating
reporting guidelines for randomized control trials for livestock
and food safety’’ (71–75). The modifications to the
CONSORT checklist recommended for livestock populations
in the REFLECT statement for livestock and food safety
intervention studies are presented in Table 1. While many of
the checklist items from the CONSORT statement remain
unchanged, the modifications made for documentation of
livestock trials (71–75) specifically addressed the common
use of group housing and group allocation to intervention in
livestock studies, the use of deliberate challenge models in
some trials, and common use of non-clinical outcomes, such
as contamination with a foodborne pathogen. In addition, the
REFLECT statement for RCTs in livestock populations
proposed specific terms or further clarified terms as they
pertained to livestock populations. The term ‘‘participant’’ in
the original CONSORT statement was limited to refer only to
animals’ owners/managers, who consent to participation in the
trial. The term ‘‘study unit’’ was preferred and recommended
in the REFLECT statement for the units within the study. This
term was used instead of ‘‘animal unit,’’ as it is common that a
part of an animal, such as a hoof, teat, or eye, be allocated to
treatment. Study units may further be classified as allocation
units and outcome units. For example, a study may allocate
udder halves to receive the treatment; therefore, the allocation
unit is the udder half. However, the outcome may be measured
on the individual teat (i.e., the outcome unit).
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The objective of this explanation and elaboration
document is to define each item modified from the
CONSORT checklist for the REFLECT statement for
livestock and food safety, to provide a rationale for its
inclusion, and to provide illustrative examples of how the item
might be reported for each REFLECT item. The examples are
derived from previously published studies in the animal
health/production and pre-harvest food-safety literature.
DEFINITIONS
Challenge trial: A study design where the investigator
controls allocation to intervention and disease occurrence.
In therapeutic challenge trials, the investigator uses a model
to induce disease, and then allocates the study units to
receive the therapeutic intervention. The outcome of interest
is often clinical improvement. In therapeutic challenge trials
with health and production outcomes, the condition of
interest is commonly exposure to an infectious pathogen or
a metabolic disease, such as fatty liver in dairy cattle.
In preventive challenge trials, the investigator allocates
the study units to receive the preventive intervention, then
uses a disease model to induce disease. The outcome of
interest is often prevention of clinical signs. For preventive
challenge studies with food-safety outcomes, the study often
ensures exposure to the pathogen of interest. Although
challenge trials do not always involve an infectious-disease
outcome, this is a common model in livestock populations
and therefore, throughout the text, most references to
challenge trials are limited to infectious-agent models.
Study unit: The term ‘‘study unit’’ refers to the units
within the study; synonyms may be the ‘‘unit of concern’’
or ‘‘experimental unit.’’ Examples of study units may be a
hoof, teat, eye, animal, pen, or barn.
Allocation unit: This term refers to the study unit that is
randomly allocated to receive the intervention. The allocation
unit can occur at only one level of the organizational structure.
For example, in a swine study evaluating the impact of
a water-based vaccine on weight gain, barns may be
randomly allocated to receive the water-based vaccine or a
placebo; therefore, the allocation unit is the barn. In a
challenge study evaluating the impact of a chilling process
intervention on the prevalence of Campylobacter on poultry
carcasses, carcass halves may be randomly allocated to
receive either processing method A or B; therefore, the
allocation unit is the carcass half.
Outcome unit: This term refers to the unit at which
outcomes are measured. Common outcomes in livestock
production are weight gain, disease occurrence, or the presence
or absence of an infectious disease agent. The outcome unit
can occur at only one level of the organizational structure, and
may be at the same level of the organization structure as the
allocation unit, or at a lower level. For example, in a swine
study evaluating the impact of a water-based vaccine on weight
gain, barns may be randomized to receive the intervention;
therefore, the unit of allocation is the barn. If weight gain was
measured by weighing all animals in the pen on a group scale
at the end of the study period (i.e., individual weights are not
available), then the outcome unit is the pen. Alternatively, if
weight gain was measured by weighing each animal
individually, then the outcome unit is the animal, i.e., there
are multiple outcome units within the allocation unit. However,
in a challenge study evaluating the impact of a chilling process
on the prevalence of Campylobacter on poultry carcasses,
carcass halves may be randomly allocated to receive the
intervention. If the presence or absence of Campylobacter is
also measured on carcass halves, then the outcome unit is the
carcass half, which is also the allocation unit.
Primary outcome: The primary outcome refers to an
outcome variable of interest, the expected value of which is
used to determine the study sample size. If researchers have
more than one outcome of interest, the sample size will be
determined by the outcome needing the highest sample size,
and this will be the primary outcome.
Secondary outcome(s): Another outcome measure,
potentially equally important, but not used to determine the
sample size. There may be more than one secondary outcome.
Level of organizational structure: The level of
organizational structure refers to the manner in which the
allocation and outcome units are organized within a produc-
tion system. The organizational structure may not always be
hierarchical (i.e., not always nested).
EXAMPLES OF ORGANIZATIONAL STRUCTURE
In a swine study evaluating the impact of a vaccine on
piglet mortality, the animals may be at the bottom of an
organizational structure that could include (1) the production
company, (2) the site within the production company, (3) the
barn within the site, (4) the pen/room within the barn, (5) the
sow within the room, and (6) the piglet within the sow’s litter.
In this example, a hierarchy, or nested structure, is apparent.
In a feedlot-based cattle study evaluating the impact of
metaphylaxis with an injectable antibiotic on the occurrence
of respiratory disease in cattle, the cattle may be at the
bottom of an organizational structure that could include (1)
the originating farm or order buyer, (2) the receiving feedlot,
(3) the truckload, and (4) the pen. In this situation, the
nested hierarchy apparent in the piglet example (see above)
does not exist, as different order buyers may have multiple
truckloads, which are mixed in different pens.
REFLECT CHECKLIST ITEMS
In this section, square brackets ([ ]) indicate that
explanatory information has been inserted into the quoted
text by the REFLECT statement authors to clarify the
quoted text. Citations originally included in the quoted text
have been removed to avoid confusion.
Title and Abstract
Item 1
How study units were allocated to interventions (e.g.,
‘‘random allocation,’’ ‘‘randomized,’’ or ‘‘randomly as-
signed’’). Clearly state whether the outcome was the result
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TABLE 1. Checklist of items for the REFLECT statement: reporting guidelines for randomized control trials in livestock and food safetya
Paper section and topic Item Descriptor of REFLECT statement item
Reported
on page no.
Title & Abstract 1 How study units were allocated to interventions (e.g., ‘‘random allocation,’’
‘‘randomized,’’ or ‘‘randomly assigned’’). Clearly state whether the outcome was
the result of natural exposure or was the result of a deliberate agent challenge.
Introduction
Background 2 Scientific background and explanation of rationale.
Methods
Participants 3 Eligibility criteria for owner/managers and study units at each level of the
organizational structure, and the settings and locations where the data were
collected.
Interventions 4a Precise details of the interventions intended for each group, the level at which the
intervention was allocated, and how and when interventions were actually
administered.
4b Precise details of the agent and the challenge model, if a challenge study design
was used.
Objectives 5 Specific objectives and hypotheses. Clearly state primary and secondary objectives
(if applicable).
Outcomes 6 Clearly defined primary and secondary outcome measures and the levels at which they
were measured, and, when applicable, any methods used to enhance the quality of
measurements (e.g., multiple observations, training of assessors).
Sample size 7 How sample size was determined and, when applicable, explanation of any interim
analyses and stopping rules. Sample-size considerations should include sample-
size determinations at each level of the organizational structure and the
assumptions used to account for any non-independence among groups or
individuals within a group.
Randomization—Sequence
generation
8 Method used to generate the random allocation sequence at the relevant level of the
organizational structure, including details of any restrictions (e.g., blocking,
stratification).
Randomization—Allocation
concealment
9 Method used to implement the random allocation sequence at the relevant level of the
organizational structure (e.g., numbered containers or central telephone),
clarifying whether the sequence was concealed until interventions were assigned.
Randomization—
Implementation
10 Who generated the allocation sequence, who enrolled study units, and who assigned
study units to their groups at the relevant level of the organizational structure.
Blinding (masking) 11 Whether or not participants those administering the interventions, caregivers and
those assessing the outcomes were blinded to group assignment. If done, how the
success of blinding was evaluated. Provide justification for not using blinding if it
was not used.
Statistical methods 12 Statistical methods used to compare groups for all outcome(s); clearly state the level of
statistical analysis and methods used to account for the organizational structure,
where applicable; methods for additional analyses, such as subgroup analyses and
adjusted analyses.
Results
Study flow 13 Flow of study units through each stage for each level of the organization structure
of the study (a diagram is strongly recommended). Specifically, for each group,
report the numbers of study units randomly assigned, receiving intended treatment,
completing the study protocol, and analyzed for the primary outcome. Describe
protocol deviations from study as planned, together with reasons.
Recruitment 14 Dates defining the periods of recruitment and follow-up.
Baseline data 15 Baseline demographic and clinical characteristics of each group, explicitly providing
information for each relevant level of the organizational structure. Data should
be reported in such a way that secondary analysis, such as risk assessment, is
possible.
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of natural exposure or was the result of a deliberate agent
challenge.
Examples
A randomized herd-level field study of dietary interactions
with monensin on milk fat percentage in dairy cows (32).
Efficacy of a novel trivalent inactivated vaccine against the
shedding of Salmonella in a chicken challenge model (23).
Explanation
Citation databases frequently search for citations on the
basis of abstract and title. The inclusion of terms that
include the word ‘‘random,’’ such as ‘‘random allocation,’’
‘‘randomized,’’ ‘‘randomization,’’ or ‘‘randomly assigned’’
in the title and/or abstract will allow easy identification of
this study design for people conducting electronic data
searches to identify evidence for the efficacy of interven-
tions, and those conducting systematic reviews.
Further, there are important differences with respect to
the external validity of studies using models of disease, as
occurs in challenge trials, versus natural development of the
disease, as occurs in field trials, particularly for infectious
diseases. Challenge trials often take place under controlled
experimental conditions, with a single pathogen in a restricted
population. Consequently, the external validity of the
challenge study may not compare favorably to the same trial
conducted under commercial conditions using a natural
disease exposure. Therefore, the identification of a trial as
having used natural or deliberate exposure allows for the rapid
differentiation of these studies. We strongly encourage the use
of ‘‘field trial’’ or ‘‘clinical trial’’ to describe studies
associated with natural development of the disease and
‘‘challenge study’’ or ‘‘challenge trial’’ or ‘‘challenge model’’
for studies which use induced models of disease.
Introduction
Item 2
Scientific background and explanation of rationale.
Example
The success of commercial dairies depends on a reliable supply
of healthy replacement heifer calves with good genetic
potential for milk production. Several management practices
have been recommended to producers for reducing the
frequency of calf morbidity and mortality on dairy farms.
One area commonly emphasized is the calving pen. The
management of calving pens influences the degree of early calf
exposure to infectious environmental pathogens (82).
Explanation
The introduction should provide sufficient contextual
background, as it relates to the study topic, to provide the
reader with a basic understanding of the underlying science
upon which the study was based. This should include a
description of the nature, scope, and extent or magnitude of the
problem under study, the pathophysiological basis for active
components in the proposed treatment, or the justification for
considering a new treatment regimen when there is an existing
treatment, as well as any other factors known to influence the
outcome and interpretation of data for the study topic.
Authors should indicate whether the intervention is
directed at a single component or multiple components
associated with the etiology of the naturally occurring
disease. For instance, challenge trials or field trials may test
the efficacy of an intervention against specific bacteria,
whereas natural development of the disease may be
associated with multiple organisms. Providing this infor-
mation in the introduction provides the reader with the
context necessary for the interpretation of the study results.
TABLE 1. Continued
Paper section and topic Item Descriptor of REFLECT statement item
Reported
on page no.
Numbers analyzed 16 Number of study units (denominator) in each group included in each analysis and
whether the analysis was by ‘‘intention-to-treat.’’ State the results in absolute
numbers when feasible (e.g., 10/20, not 50%).
Outcomes and estimation 17 For each primary and secondary outcome, a summary of results for each group,
accounting for each relevant level of the organizational structure, and the
estimated effect size and its precision (e.g., 95% confidence interval).
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including subgroup
analyses and adjusted analyses, indicating those pre-specified and those exploratory.
Adverse events 19 All important adverse events or side effects in each intervention group.
Discussion
Interpretation 20 Interpretation of the results, taking into account study hypotheses, sources of potential
bias or imprecision, and the dangers associated with multiplicity of analyses and
outcomes. Where relevant, a discussion of herd immunity should be included. If
applicable, a discussion of the relevance of the disease challenge should be
included.
Generalizability 21 Generalizability (external validity) of the trial findings.
Overall evidence 22 General interpretation of the results in the context of current evidence.
a Text in bold are modifications from the original CONSORT description.
J. Food Prot., Vol. 73, No. 3 REFLECT STATEMENT 583
The introduction section also should provide a rationale
justifying the need for the research. This may include an
identification of knowledge gaps, as well as an indication as to
how the current study will enhance our knowledge in the topic
area. The authors should provide an overview of the current
state of knowledge, based on other published studies. If
available, the authors should reference any systematic reviews
completed for the same or related interventions. The
CONSORT statement (64) suggests that, for some human
disease processes, a formal review of the published literature
may be the preferred course of action over carrying out
another (unnecessary) primary study. In livestock species,
there is a paucity of primary studies for many interventions,
and systematic reviews are not yet commonly used (90).
Many veterinary and food-safety journals prefer that the
specific objectives be included in the final paragraph of the
introduction section. In the CONSORT statement, the
objectives were described in Item 5 in the methods and
materials, and the REFLECT statement left the item relating
to the study objectives as Item 5, although we recognize that
the introduction often will be an appropriate place for this
information.
Methods
Item 3
Eligibility criteria for owners/managers and study units
at each level of the organizational structure, and the settings
and locations where the data were collected.
Examples of Eligibility Criteria
Study farms were initially identified through private veteri-
nary practices (PVP), which had submitted any kind of cattle
samples for diagnosis to the Veterinary Laboratories Agency’s
regional laboratories (VLA RL) during the previous 12
months as previously described. The cattle farms within each
PVP, who submitted the largest number of samples in the
previous year, were included and further suggestions of
potentially interested farmers from the PVP were also
accepted. Neighboring farms were excluded. A total of 411
farms distributed throughout England and Wales were
contacted by phone to assess willingness to participate in
the study and eligibility of the herd by questionnaire. Farms
were eligible, if they retained more than 60 cattle including 20
young stock, had a bovine tuberculosis-negative status, and
the premises were not shared with any public access
enterprises such as open farms, Bed & Breakfast or farm-
shops including selling unpasteurized milk (34).
Animals that arrived at the feedlot between October 16, 1994,
and December 13, 1994, were candidates for the trial. In this
study, the case definition for UF [undifferentiated fever] was
an elevated rectal temperature (.40.5uC) and a lack of
abnormal clinical signs referable to organ systems other than
the respiratory system within 3 wk after arrival at the feedlot.
Exclusion criteria were moribund animals and animals with a
previous treatment history for any disease (50).
Explanation
All trials address an issue relevant to a population of
interest, i.e., the target population; however, for logistic
reasons, trials use eligibility criteria to define a study
population. Study unit selection on the basis of eligibility
criteria may lead to meaningful differences between the
target population and the study population; therefore, these
eligibility criteria must be stated explicitly to enable the
reader to assess differences between the study and target
populations and ultimately assess external validity of
findings. It is not necessary to describe both eligibility
and exclusion criteria, as study units that do not fit the
eligibility criteria are excluded.
In the human medical field, this item generally relates
to eligibility criteria for participants and restriction of the
trial setting to one or more medical centers (5). In livestock
trials, the concept of ‘‘participant’’ refers to the owner or
manager of the animals who consents to participate in the
trial. Thus, it is important to report eligibility criteria of the
owner/manager and also eligibility criteria for the study
units. Livestock studies frequently need to consider multiple
levels of organizational structure when the study units are
enrolled. For example, for evaluation of the efficacy of
swine vaccines, the following are usually enrolled: owners
of the facilities, barns within the facilities, pens within the
barns, and finally pigs within the pens. Decisions made
about eligibility criteria at each organizational level may
influence differences between the study population and the
target population and should be reported.
Frequently, the only determinant of eligibility for a
facility may be a personal relationship with the researcher or
a veterinary practice and willingness to co-operate by the
owners/managers, or the proximity to the researchers’
laboratories. If such convenience sampling is used, this
should be stated. In other situations, facilities may be
selected randomly from a sampling frame, such as a
premises identification database or livestock commodity
organization or program list. In some instances, farms may
be selected on the basis of the presence or frequency of
occurrence of the disease of interest.
At the study-unit level, eligibility criteria commonly
include age or production stage, sex, co-morbidities, or
previous treatments. For example, it is common for livestock
production trials to exclude study units with a prior history of
the disease of interest, i.e., excluding animals with an existing
antibody titer to a specific pathogen in trials that are evaluating
the efficacy of a vaccine to prevent illness due to that pathogen.
In challenge studies, it is common that only animals not
colonized by the pathogen of interest are eligible for the study,
i.e., swine colonized with Salmonella may be excluded from a
study planning to use an artificial challenge with Salmonella.
Examples of Setting and Location Information
The experiment was carried out in a mountainous area
(1,000 m above sea level) in the northwest of Spain
(6u539W, 43u219N; Sierra de San Isidro, Illano, Asturias),
where shrubby heather-gorse vegetation is dominant. Four
plots of 5,000 m2 each were established, in which the
vegetation had been improved in 2001 by soil ploughed and
dressing and sowing perennial ryegrass (Lolium perenne L.)
and white clover (Trifolium repens L.), and removing any
heather that was present. Annual rainfall in the experimental
year (2004) was 1,589 mm. During the grazing season, mean
584 SARGEANT ET AL. J. Food Prot., Vol. 73, No. 3
rainfall ranged from 36 to 111 mm/mo. Mean average
temperatures were 17.3uC in June and 10.6uC in May (78).
Broiler chicks were hatched from commercially obtained
eggs and grown to market age (56 to 63 d) on pine shavings
in floor pens (5 | 8 m) in a controlled environment-type
house. . . . All broilers were processed in the pilot plant
processing facility at the Russell Research Center (69).
Explanation
The setting and location may affect the external validity
of the study. For some diseases, it may be relevant to report
the geographic location(s) where the trial was conducted, as
the frequency of many livestock diseases and the response
to interventions varies geographically due to differences in
climate and management systems. The time of year when
the study was conducted may also be relevant to disease
frequency. When reporting time of year, the month(s) and
year should be included, and the reader should be allowed to
infer the season.
At the farm level, issues related to setting that could
influence the external validity of the study should be
described. Authors should describe the group sizes for all
relevant levels of the organizational structure, i.e., the
capacity of the facility and the number, size, and capacity of
barns/pens/cages, etc., used to house study units. Feed and
other pertinent management details and the presence or
absence of the disease of interest, or other endemic diseases,
should also be described. The nature of the management of
the facility should also be reported. As an example, there
may be differences in facility management between a
commercial operation of a large company, an independent,
privately-owned facility, and a facility operated by a
university or government research organization.
Item 4a
Precise details of the interventions intended for each
group, the level at which the intervention was allocated, and
how and when interventions were actually administered.
Example
Treatment was assigned at the heifer level within herd. Each
heifer was randomly assigned to a treatment using a random
number generator function (R Development Core Team,
2006), and the farmers were blinded to the treatment. Before
treatment, each teat-end was scrubbed with a cottonwool
pledget moistened in 70% methanol and a gland secretion
sample was collected aseptically (n ~ 4,268 glands). No
secretion was discarded before collection because there was
only a small total volume of secretion present in most glands.
If no secretion could be collected from a gland, it was recorded
as a missing sample (n~ 99 glands). Following sampling, all
4 glands within a heifer were infused with 2.6 g of bismuth
subnitrate following teat end scrubbing (n~ 268 heifers; Teat
Seal, Pfizer Animal Health NZ Ltd., Auckland, New Zealand),
or a heifer was administered with 5 g of tylosin base i.m. for
3 d at 24-h intervals (n ~ 268 heifers; Tylan 200, Elanco
Animal Health, Manukau City, New Zealand), or all 4 glands
were infused with the teat sealant and the heifer was
administered 5 g of tylosin base i.m. for 3 d at 24-h intervals
(n~ 266 heifers), or they were left as an untreated control (n
~ 265 heifers). The tip of the teat sealant cannula was inserted
approximately 3 mm into the teat canal for infusion.
Following sampling or infusion, 0.5% effective iodine was
applied by manual spraying to all teat ends. Technicians
administered the first treatment of tylosin and then left labeled
doses of tylosin for the remaining 2 treatments for farm staff to
administer (81).
Explanation
The description of the intervention(s), including the
control intervention, should be provided in sufficient detail to
allow the reader to replicate the intervention. Phrases such as
‘‘applied per labeled instructions,’’ ‘‘as per manufacturers’
instructions,’’ ‘‘standard industry practices,’’ or ‘‘routine
treatment’’ do not constitute an adequate description that can
be replicated. Differences in management or handling among
intervention groups should be included in the description of
the interventions.
The unit of allocation for the intervention(s) should be
clearly stated, and this unit must correspond with the unit of
randomization. Examples of phrases to be used include ‘‘the
barn was randomly allocated to receive either treatment A or
treatment B;’’ ‘‘the site was randomly allocated to receive
either treatment A or treatment B;’’ or ‘‘the teat was randomly
allocated to receive either treatment A or treatment B.’’ These
phrases will eliminate confusion often associated with current
descriptions. The intent is to clearly state the unit of allocation
with adequate detail, so that there is no ambiguity for the
reader of the trial report.
For pharmaceutical interventions, the minimum descrip-
tion should include the compound name, the concentration,
the dose, the delivery matrix, the route of administration, and
the frequency of administration.
For biologic interventions such as vaccinations, the
minimum description should include the organism(s) and
whether each one is a modified-live or killed product,
substance, or probiotic unit, the adjuvant, the concentration
per ml (if known), the dose, the delivery matrix, and the
route and the frequency of administration.
For surgical interventions, the minimum description
should include the training level of the person administering
the procedure, the number of people administering each
procedure, the prior number of times the person had performed
the procedure, and the post-operative care, including the use of
other post-operative treatments such as antibiotics or medica-
tions for alleviation of pain. For example, a field trial
comparing surgical versus toggle (non-surgical) repair of a
left-displaced abomasum repair should include a complete
description of the surgical procedure, including post-operative
care and how that care differed from the post-operative
treatment of cases receiving toggle intervention. For a surgical
intervention, it is important to include who performed the
procedure, as a procedure performed by farm staff versus a
veterinarian may represent different interventions.
For food-processing interventions, the minimum de-
scription should include the production process and
variables that may affect the outcome of that process. For
example, an intervention assessing chlorine concentrations
during immersion chilling in a poultry plant should describe
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the volume of water per carcass, the water refresh rate, the
water pH, the water temperature, the water hardness,
available chlorine versus total chlorine concentration, the
source of the chlorine, and the length of time of carcass
immersion for each intervention.
It is also preferable to clearly state where treatments
groups were similar, instead of leaving it to the reader to
assume the groups were the same with respect to other
factors that could affect the outcome. For example, in a
feedlot trial assessing the pen-level prevalence of Esche-
richia coli O157 in pens that received probiotic A compared
to probiotic B at arrival, it is preferable to clearly state that
all animals received the same ration or water from the same
water supply, if ration or water supply are thought to impact
E. coli O157 prevalence
If the intervention was applied to individual animals,
the authors should state whether the animals were
individually housed or housed in a group, and if so, the
number per housing group. If the intervention was applied at
the group level, the authors should clearly state the number
of animals per group. The description of housing of the
allocation units should correspond with the levels of the
organizational structure described in Item 3.
Information about the housing of the allocation units
should be described, as this information is essential for
assessing the appropriateness of the statistical analysis and the
external validity of the study. This information will also
further clarify whether the study was a field trial under normal
production conditions, a field trial using small numbers of
animals per pen (as is common in trials conducted in research
herds), or a controlled study under laboratory conditions.
In some challenge trials, non-challenged animals are
included to serve as negative controls. When this is a feature
of the trial, the number of negative controls and their
housing relative to the study units (i.e., within challenged
groups, or proximity to, and opportunity for contact with,
challenged animals) should be described.
Item 4b
Precise details of the agent and the challenge model, if a
challenge study design was used.
Examples
A mixture of three E. coli O157:H7 strains resistant to 50 g
mL21 nalidixic acid was used as inoculum for the experiment
with sheep. The mixture contained E. coli O157:H7 strains
E32511 and E318N (human isolates), and H4420nal (bovine
isolate). The three strains were cultured individually in tryptic
soy broth for 18 to 24 h at 37uC (200 rpm). The optical
density (OD640) was measured to ensure approximately equal
cell density of all cultures. Aliquots (4 mL) of each strain were
pooled with 13 mL of sterile PBS (pH 7.4) in sterile 60-mL
polypropylene containers. Subsamples were serially diluted in
PBS and enumerated by plating 100-mL aliquots in duplicate
onto sorbitol MacConkey agar amended with cefixime
(50 mg L21), potassium tellurite (2.5 mg L21) and nalidixic
acid (50 mg mL21), denoted CT-SMACnal. . . . Feed was
withdrawn 48 h before inoculation to promote establishment
of the inoculated E. coli O157:H7 in the gastrointestinal tract.
On day 0, each sheep was orally inoculated with 1010 CFU of
the three-strain mixture of E. coli O157:H7 using a 60-mL
syringe connected to a polypropylene orogastric tube. The
inoculum was followed by two 60-mL aliquots of sterile PBS
to rinse the syringe and tubing. Fecal samples were collected
from each animal on day 1, to confirm shedding of nalidixic
acid-resistant (nalR) E. coli O157:H7 (21).
The animals were divided into 2 groups of 12 cows each (6
pairs per group) that went through the protocol 4 wk apart. The
duration of the experimental period was 17 d. From d 0 to 6,
cows were fed a standard diet based on a forage mix with 50%
alfalfa silage (42% NDF and 21% CP on a DM basis) and 50%
corn silage (38% NDF and 9% CP on a DM basis) fed ad
libitum, and offered twice a day, at 0730 and 1500 h. Nutrient
composition of forage was determined on a 6500 NIR
spectrophotometer (Foss in North America, Eden Prairie,
MN) using equations of the NIRS Consortium. Vitamins and
minerals were fed to meet requirements, mixed with 1.4 kg of
corn-based concentrate. Vitamins represented 1.0% of the DM
of the concentrate (3,304 IU/g of DM of vitamin A, 1,101 IU/g
of DM of vitamin D, and 55 IU/g of DM of vitamin E) and
minerals represented 0.6% of the DM of the concentrate
(0.55% Mn, 0.55% Zn, 0.35% Fe, 0.14% Cu, 0.008% I,
0.006% Se, and 0.002% Co). On d 7, cows were restricted to
30% of the energy required for pregnancy and maintenance by
restricting the intake of a forage mix, based on equal
proportions of alfalfa silage, corn silage, and wheat straw that
was offered once a day in the morning in addition to the 1.4 kg
of concentrate previously described. Wheat straw analysis
indicated a CP content of 3.5% and 77% NDF (22).
Explanation
The precise details of the challenge model used in the
study are critically important for assessing the external
validity (Item 21). Challenge trials represent an enormously
broad spectrum of conditions. Often, challenge trials involve
exposure to infectious agents. These models of disease may
not always be associated with clinical disease; for example,
challenge models of foodborne pathogens rarely induce
clinical disease. Other models may not have an infectious
component, such as lameness models or models of
metabolic disease, such as fatty liver in dairy cattle. The
onus is on the authors to provide sufficient details of the
model used in the challenge trial to enable the reader to
assess its validity as a model for the ‘‘real’’ condition.
It is not possible to provide guidelines that adequately
describe all possible models. However, for an infectious
model, it is recommended that the following be included:
(1) The timing of challenge relative to intervention, i.e.,
X h prior to initiation of the intervention (for therapeutic
interventions), or X h after the intervention (for preventive
interventions). The length of any acclimation period should
be included.
(2) The organism used including the source, sequence
information, and passages. A statement as to whether it is
heterologous or homologous with the biological intervention.
(3) The concentration of organism per unit of delivery
matrix should be included, e.g., 2| 106 CFU per ml or per g.
It is critical that the units of concentration and the delivery
matrix are each specified. For organism challenges, the
physiological state of the challenge organism(s) may be
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relevant and, as this may be influenced by the initial
cultivation techniques, the details of cultivation and prepara-
tion prior to inoculation must be included.
(4) Dose and route of delivery matrix administered,
e.g., the challenge organisms were mixed with 100 ml
whole milk administered per os.
(5) The total amount of organism received, which is a
function of #3 and #4. This is included as a means of
checking the dose to ensure that they match.
(6) The source of the isolate used in the challenge
inoculum should be described, e.g., clinical isolate from a
pig with diarrhea, strain X from Y collection, Nth passage of
virus from cell culture.
Item 5
Specific objectives and hypotheses. Clearly state
primary and secondary objectives (if applicable).
Examples
The primary objective of this study was to investigate if
eprinomectin treatment of adult dairy cows around calving
had any beneficial effects on the calving to first insemination
interval, calving to conception interval, and number of
inseminations per conception in herds with no or limited
pasture exposure. The secondary objective was to investigate
whether bulk milk ODR [optical density ratio] could be used
to identify herds whose calving to conception interval could
benefit from eprinomectin treatment (99).
The objective of this study was to compare calf morbidity,
mortality, and weight gain in preweaned calves reared with
and without antibiotics for therapy and prophylaxis. The
study hypothesis was that calf weight gain, morbidity, and
mortality are not affected by antibiotics in the milk replacer
or given as individual therapy (9).
Explanation
The authors should state the objectives introduced in Item
2 and the corresponding null hypothesis to be tested.
Objectives (or aims) are the concepts that studies are designed
to investigate. An objective usually states a broad goal to help
direct the study. Hypotheses, while similar in concept,
specifically state what the study is setting out to support and
allow the researcher to statistically test a proposed hypothesis.
Authors should state the null hypothesis to be tested. This
documents how the authors intend to achieve the objective
and removes an uncertainty about the purpose of the research.
Some studies are conducted to show superiority of an
intervention, in which case the null hypothesis should be that
the treatments are the same with respect to the primary
outcome. Other studies are designed with the purpose of
showing equivalence or non-inferiority of an intervention, in
which case the null hypothesis is usually that the treatments
are different with respect to the primary outcome (51). There
is indication that although some studies appear to have as their
objective to assess equivalence, the null hypothesis is framed
as for superiority studies (77). By stating the null hypothesis
clearly, the author will clarify the purpose of the research. This
will enable to reader to correctly interpret the meaning of non-
significance. This information will also allow the reader to
ascertain if the sample size was correctly determined and
whether the statistical methods were appropriate. If a one-
tailed hypothesis test is used, then published studies justifying
a unidirectional treatment effect should be referenced. If there
are multiple objectives, authors should characterize them as
primary versus secondary and consider ranking within the
categories relative to their importance to the study’s focus.
Item 6a
Clearly defined primary and secondary outcome
measures.
Example
The primary outcome was IBK [infectious bovine kerato-
conjunctivitis] cumulative incidence over the study period.
The secondary outcome was weaning weight (37).
Explanation
All trials measure at least one outcome and compare
this between intervention groups. The outcomes selected for
a trial need to be linked to the objectives and hypotheses.
All outcomes should be identified and defined, and the
methods used to measure each outcome should be
described. If disease status is used as an outcome, a case
definition should be provided, and person(s) responsible for
assigning that diagnosis should be identified (e.g., owner/
manager versus veterinarian). If specific diagnostic tests
contribute to the assessment of the outcome, sensitivity and
specificity estimates should be included, as well as a
justification of why these values are applicable to the study
population. Sufficient information should be provided so
that the study could be duplicated, e.g., details such as
whether blood samples were collected from a coccygeal
vein versus a jugular vein. If a standard approach is
modified, describe the modification, rather than using
phrases such as ‘‘. . . with slight modification.’’
The primary outcome refers to the measure used to
determine the study sample size (Item 7). Other outcome
measures, which may be potentially equally important, but
were not used to determine the sample size, should be
referred to as secondary outcomes. The rationale for
differentiating the outcomes as primary and secondary is
to allow the reader to understand for which outcomes the
study had sufficient power to detect meaningful differences
in effect. In livestock trials, it is common to have one
outcome related to the disease of interest (e.g., mortality or
morbidity) and one related to performance (e.g., average
daily gain), since these indices are often of primary concern
to livestock owners. In situations where two outcomes are
truly of interest and the study is designed to have sufficient
power for both outcomes, the authors should provide
sample-size information for both outcomes (Item 7) and
describe the outcome needing the highest sample size as the
primary outcome. When an outcome is measured at multiple
times/points, the authors should specify which time point is
the primary outcome. Secondary outcomes may also be
unanticipated or unintended outcomes that become apparent
as the study progressed, and it should be stated these were
unplanned outcomes.
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The use of multiple outcomes is common in trials
conducted in livestock populations. In a review of trials of
antibiotic therapy for bovine respiratory disease, 25 of 35
studies reported multiple outcomes, and none indicated the
primary outcome (77). In a study evaluating reporting in
food-animal trials with health or production outcomes, 91 of
100 trials reported multiple outcomes, with only four trials
identifying the primary outcome (89). Of 100 pre-harvest
food-safety trials evaluated in a similar study, 91 reported
the use of multiple outcomes, with none of the trials
identifying the primary outcome (91).
Item 6b
Where applicable, any methods used to enhance the
quality of measurements (e.g., multiple observations,
training of assessors).
Examples
Corneal ulcers in the digital photographs were traced on a
computer tablet (Wacom Cintiq 15X LCD tablet, Wacom
Technology Corporation, Vancouver, WA, USA) using
public domain image analysis software (ImageJ program;
available at http://rsbweb.nih.gov/ij). Differences in magni-
fication were accounted for by standardizing the scale of
each tracing using the ruler in each photograph. The mean of
three tracings of each ulcer was used to calculate the corneal
ulcer surface area measurement; for data analysis, the square
root of the corneal ulcer surface area was used to represent
the ulcer surface area measurement (SAM). The limit of
detection was 0.008 cm2, an area corresponding to a 1-mm
diameter circle. Ulcers that appeared linear or stellate were
considered to be the result of mechanical trauma and were
not counted as ulcers associated with IBK unless the ulcer
was still present at the next weekly observation (6).
Means of bacterial populations (log10 CFU/g) from each
treatment were calculated from three replications for each
experiment (35).
Explanation
Authors should provide details of any steps used to
increase the precision or validity of an outcome measure.
For instance, use of repeated measurements of an outcome
or multiple samples may be used to define the outcome
status of a study unit. The description should include the
number of observations and the means of summarizing into
the outcome.
Standard guidelines used regarding quality of measure-
ments should be specifically cited where relevant. Limits of
detection, precision of measurements, and cutoff points
should always be described. When applicable, referencing
validated scales and consensus guidelines are recommended
to ensure transparency and reproducibility. For determina-
tion of bacterial or viral outcomes, standard procedures
should be used, if available, or deviations from standard
procedures should be justified. Resources for such standards
are available for many areas. For example, standards for
culture of mastitis pathogens in bovine milk are provided by
the Clinical and Laboratory Standards Institute and National
Mastitis Council (67, 105).
Authors should provide details on any formal study-
specific training of the outcome assessors, including details
of inter-rater agreement during training or pre-testing. This
is especially important for subjective outcomes, e.g.,
lameness, pain, body-condition scores, and physical ap-
pearance. Many livestock studies use producer-based
diagnoses of diseases, and if no additional training was
provided this should be stated.
Item 7
How sample size was determined and, when applicable,
explanation of any interim analyses and stopping rules.
Sample-size considerations should include sample-size deter-
minations at each level of the organizational structure and the
assumptions used to account for any non-independence
among groups or individuals within a group.
Examples
A sample size of 699 animals in each group was calculated to
have an 80% power to detect a difference in means of 1.5 kg,
assuming that the common standard deviation was 10 kg using
an ANOVA with a consecutive two group t-test and a 5% two-
sided significance level. For compensation of possible drop
outs a total of 1542 healthy piglets from three consecutive
farrowing batches, each comprising approximately 500
animals were included into this study (36).
Sample sizes were calculated by a multi-level approach with
design-effects and intra-class correlations deducted from
variance between [fecal] pats, groups, and farms observed in
a previous field study on a similar population. The required
sample sizes were 48 control farms and 48 farms in each
intervention group to detect a risk ratio of 5 at 80% power
with 95% confidence, when using a design effect of 13.22 to
adjust for a group cluster size of 20 pat samples per group
per visit. The design effect was estimated from data
originating from a longitudinal study using the same
sampling approach along with individual animal sampling
(34).
Explanation
Use of an adequate sample size to detect treatment
differences that are economically and biologically important
is fundamental to sound trial design. The main statistical
considerations in sample-size calculation are the magnitude
of the effect size (e.g., difference in proportions, means,
survival times, etc.), standard deviation of the outcome,
power (1 2 b [type II error]~ probability of accepting the
null hypothesis when it was not true) and the significance
level (a ~ type I error ~ the probability of rejecting the
null hypothesis when it was true). Typically, power and
significance values of 80% and 5%, respectively, are used
in calculations. The effect size that can be detected is
inversely related to sample size—the smaller the difference,
the larger the group sizes. The most common problem is
lack of adequate sample size, while use of more animals
than is necessary is also an important ethical concern.
For the null hypothesis and primary outcome identified
in Items 5 and 6, authors should describe how the sample
size was determined for each level of the organizational
structure of the study setting. The description should include
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how non-independence of the outcome measurements and
exposure were accounted for in the calculations, if relevant.
If the study has multiple outcomes, and the study size
chosen was considered adequate to detect clinically
important differences for several outcomes, this should be
reported, and the assumptions used to reach this conclusion
for each outcome should be described.
Authors should state the basis for assumed values of the
outcomes in the treatment groups, citing published studies
whenever possible. For example, a 10% absolute difference
in cumulative incidence could occur if the treated and
untreated groups had incidences of 10% and 0% or 50%
and 40%, respectively, but the sample size required to detect
the latter scenario would be greater.
In trials with long-term follow-up in production animal
systems, there can be substantial loss to follow-up. For
example, in a 3-year follow-up study of 100 cows in a dairy
herd with 30% annual culling, only 33 of the originally
enrolled cows would be expected to remain. How the
anticipated loss to follow-up was accommodated should be
described in later items (Item 13, Item 16, Item 20, Item 21),
as this may have a large effect on internal validity.
Sample size should not be confused with the specimen
size. Sample size (the number of study units) and specimen
size (e.g., use of 10 g of feces versus 25 g of feces for
laboratory culture of enteric pathogens) have distinct
meanings. Specimen size should be included in Item 6
(description of the outcome measures).
Example of Stopping Rules (from
Human-Health Literature)
Primary end points were progression free survival, response
rate, and toxicity. Overall survival was a secondary end
point. Two analyses were initially planned. The first analysis
was to assess and compare response rates after 21 patients
were recruited to each group. If one of the groups had had a
response rate less than 10% and if a difference greater than
15% in response rate was observed between the two groups,
the study would have been stopped. If not, the trial could
continue as a phase III study. The final planned sample size
was then 91 patients in each group, on the basis of detection
of a 15% difference in progression free survival between the
two arms (15% v 30% at 1 year) with a two sided test, an
alpha risk of 5%, and a power of 80% (68).
Explanation
The consensus meeting members were unaware of any
livestock studies with production, health, or food-safety
outcomes that reported trials using stopping rules. There-
fore, no examples from this literature could be provided, and
the explanation for this item is quoted from the example
used in the CONSORT statement elaboration document.
There are many situations where stopping rules may be
applicable or useful in livestock production, and further, there
are likely many published situations where authors take
‘‘looks’’ at the data before the end of the study. It is not
uncommon for clinical trials to sequentially recruit study units
on the basis of the availability of specific inclusion criteria
and, in some instances, recruitment may occur over a long
period of time. If an intervention is particularly efficacious, or
if it causes harm, it may be ethically appropriate to end the trial
early. Trials stopped early for harm should result in
discontinuation or decreased use of potentially harmful
interventions, and trials stopped early for benefit should
contribute to earlier market availability of efficacious
treatments. In the human health-care literature, RCTs stopped
early for benefit are becoming increasingly common (66).
However, this decision requires that the data be examined at
one or more time points during the course of the trial. This
raises statistical concerns, because the multiplicity of testing
increases the probability of a type I error and the identification,
as significant, of random fluctuations towards greater
treatment effects (95). In an example provided in the original
CONSORT elaboration document, if accumulating data from
a trial were examined at five interim analyses, the overall
false-positive rate would be nearer to 19% than to a nominal
5% (5). Statistical methods are available for stopping
procedures (95), and their use should be pre-specified in the
trial protocol if interim analyses are planned. These methods
generally make use of a small P value to aid in decision
making or for use as a formal stopping rule (5). The decision
to stop trials early is controversial; a systematic review of trials
stopped early for benefit reported implausibly large treatment
effects, particularly when the number of events was small
(66). An extension of this review is ongoing to further
understand the extent to which trials stopped early may
exaggerate treatment effects (11).
Item 8
Randomization (sequence generation). Method used to
generate the random allocation sequence at the relevant
level of the organizational structure, including details of any
restrictions (e.g., blocking, stratification).
Example
Each heifer was randomly assigned to a treatment using a
random number generator function (R Development Core
Team, 2006). . . . (81).
Explanation
Randomization is essential to internal validity, as it is
designed to minimize differences between the treatment
groups and can be implemented in most RCTs, regardless of
level of intervention allocation. Study units should be assigned
to groups on the basis of chance (i.e., a random process) to
limit the potential for confounding to influence the study result
or for selection bias in the assignment of study units to
treatment groups. The term ‘‘random’’ has a precise meaning,
wherein each study unit has a known probability of receiving a
given treatment prior to assignment of the treatments. The
actual treatment that a specific study unit is allocated is
determined by a chance process and cannot be predicted. The
methods used to generate the random allocation sequence
should be reported in sufficient detail to allow the reader to
assess the likelihood of bias in group assignment. Many
methods of sequence generation are adequate. However,
readers cannot judge the adequacy from such terms as
‘‘random allocation,’’ ‘‘randomization,’’ or ‘‘random’’ with-
out further elaboration. Therefore authors should specify the
J. Food Prot., Vol. 73, No. 3 REFLECT STATEMENT 589
method of sequence generation, such as a random-number
table or a computerized random-number generator.
Deterministic allocation methods, such as alternate
animal identification numbers, days of the week, date of
birth, birth order, and gate cutting are not random (94). When
these methods are used, they should not be described using the
term ‘‘random’’ or any variation of it. There is evidence in
trials involving livestock that the term ‘‘random’’ is misused
to describe non-random processes, e.g., a process such as gate
cutting (77).
When authors do not use random methods to allocate
study units to treatment groups, the method of allocation
should be described in a manner that would allow the reader
to determine if bias was likely to be introduced due to the
lack of randomization. The use of terms such as ‘‘systematic
randomization’’ and ‘‘quasi randomization’’ to describe
these methods of allocation is not appropriate without
further elaboration.
Often there are valid reasons to avoid simple random-
ization and to employ instead a restricted randomization
method. The description of restrictors on randomization are
provided in the CONSORT statement Explanation and
Elaboration document and other references (5, 19). Block
randomization, also called permuted block randomization
(19), is a method of allocation that ensures an equal
distribution of study units to intervention groups and is often
employed when the study size is small. The approach is to
divide the whole series of study units into several blocks
with equal or unequal size and randomly allocate animals to
treatment within blocks, e.g., in a study of 32 animals, there
may be eight blocks of four animals each. In challenge
studies, which often have small study sizes, consideration
should be given to employing block randomization. One
disadvantage of block randomization is the potential for
someone to deduce the intervention if they are aware of the
block size. This risk can be mitigated by varying the block
size randomly, i.e., blocks of two, four, and six within a
study. An excellent description of how to implement block
randomization is available (2). Block randomization may
also be useful for field studies with group-level units of
allocation, such as pen-level studies. In a pen-level study
comparing two treatments with 20 pens per treatment, it
may be sensible to use 10 blocks of four pens each to ensure
every group of four pens enrolled has two treated and two
untreated pens (19).
Stratified randomization includes a covariate (thought
to be a confounder) in the allocation sequence determina-
tion. For example, a feedlot study may stratify by heifers,
bulls, and steers and use block randomization within each
stratum to allocate to treatment group, or a swine study may
control for the effect of sow and weight using stratified
randomization, e.g., piglets ordered by weight from heaviest
to lightest within a litter (a sow) and allocated to treatment
in blocks of two piglets. Stratified randomization requires
that block randomization be used within the strata to ensure
balance of treatments within strata (2).
Minimization may also be used with small sample size
trials to minimize differences between groups with respect
to important prognostic or confounding variables. In this
approach, the first study unit is assigned to treatment group
using a random method; thereafter, allocation to treatment
group is based on minimizing the differences among groups
based on the pre-selected factor(s) (106).
Item 9
Randomization (allocation concealment). Method used to
implement the random allocation sequence at the relevant
level of the organizational structure (e.g., numbered contain-
ers), clarifying whether the sequence was concealed until
interventions were assigned.
Examples
Sealed envelopes numbered 1 through 120 were prepared
that assigned each cow to the laparoscopy-assisted aboma-
sopexy or control group. These envelopes were opened only
after confirmation of eligibility and immediately before
surgery (97).
The remaining 57 farms were randomly allocathed into three
intervention groups and one control group. . . . The allocation
was done blindly by a clerk, who assigned each participating
farm a random letter drawn from an envelope, which contained
one letter for each intervention group and . . . for the control
group (34).
Explanation
Authors should describe whether or not any steps were
taken to conceal allocation sequence until after the study unit
was enrolled. The aim of allocation concealment is to prevent
bias at the recruitment/enrollment phase of the trial. In a trial
with adequate allocation concealment, informed consent
should be obtained from the owner/manager, and the decision
to include or exclude a specific study unit in the trial should be
made with no knowledge of the next intervention-group
assignment in the allocation sequence. There is empirical
evidence in the human health-care literature that failure to
report allocation concealment is associated with exaggerated
treatment effects (52, 54, 55, 61, 93). Allocation concealment
differs from blinding, which aims to prevent misinformation
bias in the measurement of the outcome and differential
management of treatment groups, and is implemented after
allocation to the intervention.
An example of bias introduced due to failure to conceal
the allocation sequence may occur in a feedlot. For example,
the processing crew at a feedlot may decide not to enroll a
truckload of high-risk cattle into the study if they have an
unfavorable view of the treatment that truckload will be
allocated. Concealment of the treatment to be received until
after the cattle have been enrolled would prevent the
introduction of such a bias. Similarly, in a dairy cattle study,
the owner/manager may wish certain cattle to be assigned to
the treatment group because of their genetic value or
severity of disease. If the person implementing the
allocation sequence is unaware of the next assignment, the
person is not able to be consciously or unconsciously
influenced by the owner’s preference. Currently, it is not
common for livestock studies to use formal allocation
concealment. However, inadequate allocation concealment
can subvert the random allocation process (94).
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Item 10
Randomization (implementation). Who generated the
allocation sequence, who enrolled study units, and who
assigned study units to their groups at the relevant level of
the organizational structure.
Example
Prior to the ISU [Iowa State University] farm visits,
containers holding the autogenous vaccine and placebo were
re-labeled injection A or B by staff who would not enroll
animals at the farm. A chute processing order sheet was
created, and a corresponding random allocation number
between 0 and 1 was generated by an investigator not
involved with enrollment (Excel, Microsoft, Redmond,
WA).... At the ISU farm, three students, including the 1st
author allocated the animals to treatment cohorts (37).
Explanation
In order for the reader to evaluate allocation conceal-
ment, it is necessary to know who generated the allocation
sequence, who enrolled study units into the trial, and how
study units were allocated to the treatment groups. Ideally,
the person(s) who generated the random allocation sequence
should not be involved in the enrolment and assignment of
study units to the treatment groups, as this could result in
bias. In the human health-care literature, the concern of not
separating allocation generation from implementation is
that, if the person who generated the allocation sequence is
the same person who enrolls participants or assigns
treatment, knowledge of the allocation sequence could
influence them when interviewing potential trial participants
(94). In trials in livestock populations, this bias could occur
when selecting study units for participation, or could be
inadvertently introduced when communicating with owners/
managers on potential study units for inclusion. In some
instances, owners/managers may be the person(s) enrolling
study units, in which case they should not be aware of the
allocation sequence, for the same reasons.
Item 11
Whether or not those administering the interventions,
caregivers, and those assessing the outcomes were blinded
to group assignment. If done, how the success of blinding
was evaluated. Provide justification for not using blinding if
it was not used.
Example
Two bottles, labeled ‘‘A’’ and ‘‘B,’’ were provided to each
feedlot, so that the feedlot personnel were blind to the status of
the vaccine. One bottle held the vaccine. . . . The other bottle
held the placebo, which was the same as the vaccine but
without the antigen (108).
Explanation
In controlled trials, blinding (synonym: masking) refers
to the process of keeping different individuals involved in
the trial unaware of the group allocation. Blinding is
associated with internal validity and can be implemented in
most RCTs, regardless of level of intervention allocation.
The use of blinding often is reported poorly in livestock
trials; only four of 100 randomly selected livestock trials
with health or production outcomes, and zero of 100
randomly selected pre-harvest food-safety trials, reported
blinding of the person administering the treatment and
blinding of the outcome assessor (89, 91).
Trials which failed to report blinding and randomization
in a systematic review of vaccines to prevent pinkeye in cattle
were more likely to report favorable outcomes compared to
trials that did report randomization and blinding (47% versus
20%) (14). This is consistent with studies in the human-health
literature that have observed larger treatment effects in trials
not reporting the use of blinding (52, 54, 93).
It is insufficient to state ‘‘staff were blinded to intervention
groups’’; the process of achieving blinding should be reported.
As with allocation, the method of blinding should be described
to allow the reader to assess the validity of the blinding. The
terms ‘‘single-, double-, and triple-blinded’’ may be used to
describe the blinding, but such terms are ambiguous; a study in
the human health-care literature illustrated that individuals may
have different interpretations of who is blinded when these
terms are used (27). Also, study subjects in animal studies
cannot be blinded, unlike human study subjects. Therefore, it is
preferable to state which individuals were blinded. In livestock
studies involving production, health, and food-safety out-
comes, we propose that authors address three potential levels
of blinding: individuals associated with assessment of the
outcome, individuals caring for the animals, and data analysts.
Individuals associated with assessment of the outcome may
include owners/managers, animal caregivers, data collectors,
and assessors of outcomes (26). The personnel who are blinded
should be explicitly described in this item and their role in the
study defined (e.g., veterinarians, data analysts, personnel in
laboratories performing tests).
The rationale for blinding individuals responsible for
assessing the outcome is to prevent introduction of
information bias. If the assessor is aware of the groups,
they may over- or under-estimate the outcome. Even
objective outcomes such as weight gain may be biased by
the lack of blinding. For example, in a study evaluating the
impact of an intervention on the presence of Salmonella spp.
on poultry carcasses at an abattoir, laboratory staff may re-
examine plates more frequently, looking for Salmonella
spp., if they are aware that a set of plates is associated with a
particular intervention group expected to have higher
Salmonella recovery rates. The CONSORT explanation
and elaboration refers to this as ascertainment bias.
Further, it is also critical that anyone responsible for
animal-care decisions is unaware of the group allocation.
Knowledge of the intervention by caregivers may lead to
differential care of the groups, which may introduce
performance bias. For example, a challenge trial may be
designed to assess the impact of a vaccine on the presence of
clinical signs of respiratory disease after challenge. The study
protocol may include a blinded person responsible for
allocation of the intervention (described in Item 9), an
unblinded caregiver, and a blinded outcome assessor. The
primary and secondary outcomes of interest may be the
presence of sneezing and coughing at a certain time of day,
and 21-day weight gain, respectively. This study protocol may
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not prevent the introduction of bias if the unblinded caregiver
increases observations of a particular intervention group and
administers antibiotics to animals in the group at an earlier
stage of disease. Increased administration of antibiotics may
affect the prevalence of clinical signs and weight gain in that
group, thus introducing a bias into both outcomes, although
the outcome assessor is blind to the group allocation.
It is not always possible to use blinding, for example, if
the intervention is a comparison between a surgical
treatment and a medical treatment. In challenge studies, it
may be difficult to maintain blinding if challenged animals
become morbid and there is a pronounced treatment effect.
If the study cannot be blinded, authors should describe
why it was not and how the study was adapted to eliminate
selection and/or information bias. This should include the
use of at least one objectively measured outcome.
Item 12a
Statistical methods used to compare groups for all
outcome(s). Clearly state the level of statistical analysis and
methods used to account for the organizational structure,
where applicable.
Example
The experimental unit used for statistical analyses was
individual mammary quarter. Generalized linear mixed
models were used to examine risk factors for development
of a new IMI [intra-mammary infection]. Specialized
statistical techniques were used to account for clustering of
quarters within cows and for clustering of cows within herds
[referenced in original article]. It was assumed that the
degree of similarity between observations within a cluster
was the same for all clusters. The main predictor of interest
was treatment, and models with the following outcomes were
analyzed: new IMI caused by any pathogen, new major IMI,
new environmental IMI, new gram-negative IMI, and new
streptococcal IMI. For each outcome, a single model that
incorporated terms for group and treatment within group was
constructed (88).
Explanation
A complete and accurate description of statistical
analyses allows the reader to assess the validity of the
statistical methods and the likelihood that analytical bias
affected the internal validity of the study. The statistical
analysis of RCT data should follow logically from the
design of the study. Particular care is needed analyzing data
from a trial where the units of allocation and outcome
measurement are not the same. Ignoring differences between
the unit of allocation and the unit of outcome measurement
may lead to spurious results (15, 31, 102). It is critical that
authors clearly describe the statistical approach to analysis
employed to account for such a design. Several statistical
methods of data analysis may be suitable, depending on
whether the outcome measurement is continuous, ordinal, or
binary. There are many useful publications that appropri-
ately describe the statistical methods to use, and consulta-
tion with a statistician in the design and analysis stage of a
clinical trial is strongly recommended (102). Further,
authors are encouraged to consult texts that describe how
to write about statistical methods, as the following notes do
not cover all possible contingencies (59).
The statistical procedure to analyze each outcome
should be explicitly described. Authors should report
underlying assumptions associated with each analysis
(e.g., normally distributed data) and, when conducted, data
transformations should be stated and justified.
The assumption of independence and identical distribu-
tion is commonly violated in livestock studies when there are
multiple repeated observations per study unit over time and/or
when study units are aggregated in groups and the outcomes
of multiple groups are considered in the analysis. Therefore,
independence and identical distribution should be considered
and where necessary, clearly described and justified. Treating
each observation as an independent event when the
organizational structure of the population implies non-
independence is a serious violation of inherent assumptions
of many statistical tests and usually leads to an overly
optimistic P value (the probability of observing the data or a
more extreme result when there is no treatment effect). The
statistical approach used to account for non-independence
should be clearly described. An extension of the CONSORT
statement for clustered trials has been developed and provides
recommendations for reporting this type of trial (16).
Authors should provide details of all descriptive and
hypothesis testing analyses that were conducted, including
the name of the test used, such as t-test, chi-square for
proportions, Fisher exact, Mann-Whitney, or others. If the
method is novel, a reference for the approach should be
provided. If logistic regression modeling is used, the level of
the outcome being modeled should be described, for
example, ‘‘we modeled the probability of being disease-
positive.’’ For all models, authors should indicate the data
form (e.g., continuous or categorical) for all variables in the
model. For categorical intervention variables, the referent
must be clearly stated, for example, ‘‘the referent level of
the intervention was Treatment A.’’ Guidelines for reporting
regression models are available (79, 104).
Item 12b
Methods for additional analyses, such as subgroup
analyses and adjusted analyses.
Example
Bacterial and clinical cures among groups were compared by
chi-square tests. A stratified analysis of treatment effects was
then performed to compare these effects with those after
stratification on farm (three levels) and pretreatment bacterial
isolates (four levels). These analyses determined whether the
treatment effects were independent of farm and primary
bacterial isolate (45).
Explanation
In RCTs, randomization should limit the impact of
confounding on the study outcome. Therefore, there is
generally no need to adjust for confounding. Further,
adjustment for statistically significant baseline differences
is not recommended (12, 13, 46, 80, 111). Therefore, if
authors wish to explore confounding using multivariate
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analysis, the rationale for assessment of confounding should
be provided. Although confounding by important prognostic
variables should be removed through randomization of
treatments, it may still be of interest to a researcher to
investigate interactions between the treatment groups and
important covariates. If the interactions are significant, it
may be necessary to conduct subgroup (or strata-specific)
analyses. If subgroup analyses are used, the method should
be clearly described. However, post hoc subgroup analysis
is discouraged, as these comparisons may result in spurious
results by increasing the number of comparisons evaluated,
and the sample size is generally calculated on the basis of
the full sample rather than the sample size provided by a
subgroup. Therefore, subgroup analyses generally do not
have credibility, and their findings are often not confirmed
by subsequent studies.
Subgroup analysis often employs multivariate regres-
sion models with interaction (cross-product) terms to assess
the presence of effect modification. If regression modeling
is used, the authors should describe the test used to assess
the significance of the interaction term. Further, the outcome
being modeled, the variables of interest, and covariates
included in the model should be clearly stated. For all
models, authors should indicate the data form, continuous or
categorical, for all variables in the model. For categorical
variables, the referent should be identified. Authors are
encouraged to refer to guidelines for reporting regression
models (79, 104). This information is necessary to allow the
reader to assess the validity of the adjusted or subgroup
analyses and the likelihood of analytical bias.
Results
Item 13a
Flow of study units through each stage for each level of
the organizational structure of the study (a diagram is
strongly recommended). Specifically, for each group, report
the numbers of study units randomly assigned, receiving
intended treatment, completing the study protocol, and
analyzed for the primary outcome.
Examples
Of the 939 cows (3,731 mammary quarters) enrolled in the
study, 519 were assigned to group 1 (results of bacteriologic
culture of all 4 quarter milk samples collected 14 days prior to
the end of lactation were negative) and 420 were assigned to
group 2 (results of bacteriologic culture of 1 or more quarter
milk samples collected 14 days prior to the end of lactation
were positive). However, 111 cows in group 1 were excluded
for the following reasons: abortion (n~ 10), disease (1), death
(7), removal from the herd (2), . . . . Similarly, 93 cows in
group 2 were excluded for the following reasons: abortion (n
~ 3), death (4), removal from the herd (3), 1 or more milk
samples were not collected (12), 1 or more milk samples were
lost (1), the incorrect treatment was given (1), the nonlactating
period lasted ,30 days (6), . . . . Thus, data from 734 cows
(408 assigned to group 1 and 326 assigned to group 2) and
2,771 quarters were included in analyses (88).
Twenty-eight of the 30 cows with LDA were successfully
surgically treated with omentopexy via right flank laparot-
omy or 2-step laparoscopy-guided abomasopexy and
discharged from the hospital. One cow in each surgery
group died or was euthanatized (both at day 7 after surgery)
because of failure to respond to treatment and subsequent
multiorgan failure. Necropsy revealed extensive hepatic
lipidosis in both cows, and data from both were included in
the statistical comparison (113).
Explanation
Authors should include the organizational levels
applicable to their trial. Table 2 contains a list modified
from the CONSORT Explanation and Elaboration document
with the details required to chart the progress of owners/
managers and study units through an RCT. For example, if
the study solicited participation from randomly selected
farms identified in a county-level database, then the number
of farms that refused to participate should be reported. For a
trial conducted on a single feedlot, which was selected by
convenience, then the narration/flow chart might begin with
a discussion of the feedlot pens selected from within the
feedlot to be included in the study.
Flow of study units in challenge trials of short
duration with no losses, no protocol failure, and no change
in organizational structure to report, may be reported
effectively in the text. However, for more complex trials,
authors should strongly consider including a flow chart of
the trial. The complexity of the organizational structure is
important to understanding the external validity, while loss
to follow-up and protocol failures affect internal validity.
Thus, the reader needs this information in order to assess
the validity of the study. For example, loss to follow-up of
barns from one production system or site may have
different implications than exclusion of barns distributed
across multiple production companies or sites. Likewise, in
livestock-production operations, animals might be sold
before outcomes are assessed and, if the sale was
associated with the outcome, this might result in biased
results. The reader may find a chart depicting these
changes easier to follow than reading a description of
events. The description of losses to follow-up or protocol
deviations should clearly identify these features at both the
level of treatment allocation and the level of outcome
measurement.
An example of loss to follow-up in a livestock study
could be a study that assessed the impact of antibiotics on
weight gain in the first 21 days post arrival. For cattle that
die prior to the end of the study period, weight gain cannot
be assessed; therefore, these study units are lost to follow-
up. In the same study, it is possible that one or more farms
could decide to terminate their involvement prior to the end
of the trial. In this example, the number of farms, pens, and
animals that were lost to follow-up should be described. In a
food-safety trial assessing the impact of a vaccine on E. coli
O157 levels on carcasses, carcasses eliminated during
processing due to condemnation cannot be assessed for E.
coli O157 status and are an illustration of study units lost to
follow-up. Samples that are collected but subsequently lost
in transit, or have illegible labels preventing accurate
identification, are also examples of follow-up losses.
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Item 13b
Describe protocol deviations from study as planned,
together with reasons.
Examples
A random binary selection process was used to determine
which pen of each pair received vaccine product, except that
in a few circumstances one pen of a pair had already received
its arrival processing before enrollment in the study;
therefore, the other pen received the vaccine (100).
Choice of surgical technique was assigned systematically to
1 of 2 groups in alternating sequence when the situation
permitted. However, because the study was conducted on
farms, choice of technique was often influenced by factors
such as needs of the producer, availability of laparoscopic
instruments, or constraints of the teaching environment (87).
Explanation
Any deviations from the trial protocol as defined prior to
the start of a trial should be described; if no deviations
occurred, this should also be clearly stated. Types of
deviations that should be described include unplanned
changes in the intervention(s), as well as changes to the
way in which data were collected or analyzed. If a flow
diagram was used to describe participant numbers at each
stage of the trial (Item 13a), it may be possible to detail some
or all of the protocol deviations in this diagram. In particular,
if the trial is not being conducted under the ‘‘intention to
treat’’ principle, the flow diagram can be used to indicate the
exclusion of study units that were found not to meet
eligibility criteria (Item 16) post randomization. However,
merely stating that a deviation occurred is not enough to
justify post-randomization exclusion—details of the deviation
and the reasons for the exclusion must both be provided. The
number of study units that withdrew prior to collection of
outcome data also should be described; if outcome data are
collected for all enrolled study units, this should be stated.
Item 14
Dates defining the periods of recruitment and follow-up.
Example
Of 437 cows (1748 quarters) initially enrolled at dry off
between March 27, 2002, and August 1, 2002, 419 cows
TABLE 2. Information required to document the flow of participants through each stage of a randomized controlled trial
Stage No. included No. not included/excluded Rationale
Enrollment Owners/managers evaluated for
potential enrollment
Owners/managers who did not
meet the inclusion criteria,
owners/managers who met
the inclusion criteria but
declined to be enrolled
This information aids in determining
whether animal owners/managers
were likely to be representative of
all owners/managers with similar
livestock operations; it is relevant
to assessment of external validity
Herds/sites/pens/animals evaluated
for potential enrollment
Proportion of herds/sites/pens/
animals meeting inclusion
criteria but not enrolled (at
each level of organization)
This information aids in determining
whether the enrolled number (the
sample population) represents a
large component of the potential
study population within the
facility; it is relevant to
assessment of external validity
Randomization Study units randomly assigned May need to be described at more
than one level of organization
(e.g., animals randomly assigned
to pens, pens randomly assigned
to treatments)
Crucial for defining trial size and
assessing whether a trial has been
analyzed by intention to treat
Treatment allocation Study units who received treatment
as allocated, by study group
Study units who did not receive
treatment as allocated, by study
group
Important for assessment of internal
validity and interpretation of
results
Follow-up Study units who completed
intervention protocol as allocated,
by study group
Study units who did not complete
intervention protocol allocated,
by study group
Important for assessment of internal
validity and interpretation of
results; also may provide
information about the feasibility
of the protocol
Follow-up Study units who received the full
intervention protocol and
completed follow-up as planned,
by study group
Study units who received the full
intervention protocol by study
group but did not complete
follow-up as planned
Important for assessment of internal
validity and interpretation of
results; also may provide
information about the feasibility
of the protocol
Analysis Study units included in main
analysis, by study group
Study units excluded from main
analysis, by study group
Crucial for assessing whether a trial
has been analyzed by intention to
treat; reasons for excluding
participants should be given
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remained in the study, calving between May 11, 2002, and
October 5, 2002 (43).
Explanation
Knowledge of the time period during which a study took
place and over what period study units were evaluated places the
study in historical context (64). Animal studies, especially those
that are conducted outdoors under field conditions, may be
influenced by seasonal and related weather effects. In addition,
unusual weather conditions, such as extremes in temperature,
drought, or excessive rain or snow, may also influence the
results. The length of the study should be included, and
conditions which may be unique to one group should be noted,
although a parallel design should avoid this issue. If a study is
conducted where the control and intervention groups start and
end on different dates, then this should be noted in the report.
Item 15
Baseline demographic and clinical characteristics of
each group, explicitly providing information for each
relevant level of the organizational structure. Data should
be reported in such a way that secondary analysis, such as
risk assessment, is possible.
Example
See Table 3.
Explanation
The aim of reporting baseline information is to
summarize the actual characteristics of the study population.
It is important for those reading trials to know the
characteristics of the study units included in the trial in
order to evaluate the internal and external validity of the trial
results. Providing information on whether the treatment
groups were comparable with respect to important demo-
graphic and clinical characteristics allows the reader to
assess the comparability of groups. Therefore, for each
group, report important characteristics of study units at all
relevant organizational levels. For example, baseline
demographics may include herd-level characteristics such
as farm size, stocking density, and geographic location,
whereas animal-level demographic variables may include
weight or age and sex.
Randomized controlled trials aim to compare groups of
‘‘study units’’ that differ only with respect to the
intervention (treatment). Although formal random assign-
ment to treatment groups should prevent selection bias, it
does not guarantee that the groups are equivalent at baseline.
However, any differences in baseline characteristics after
randomization are the result of chance rather than bias (3).
Conducting and reporting significance tests of baseline
differences is not warranted (3, 92, 98) and adjustment for
variables on the basis of statistically significant differences
at baseline is likely to bias the estimated treatment effect.
Baseline information is often efficiently presented in a
table. For continuous variables, such as weight or blood
pressure, the variability of the data should be reported, along
with average values. Continuous variables can be summa-
rized for each group by the mean and standard deviation.
When continuous data have an asymmetrical distribution, a
preferable approach may be to quote the median and a
percentile range (e.g., the 25th and 75th percentiles) (4).
Standard errors and confidence intervals are not appropriate
for describing variability; they are inferential rather than
descriptive statistics. Variables making up a small number
of ordered categories (such as stages of disease I to IV)
should not be treated as continuous variables; instead,
numbers and proportions should be reported for each
category (4, 57).
Item 16
Number of study units (denominator) in each group
included in each analysis and whether the analysis was by
‘‘intention-to-treat.’’ State the results in absolute numbers
when feasible (e.g., 10/20, not 50%).
Examples
The surgical procedure was successfully completed in 59 of
60 (98.3%) cows in the laparoscopy-assisted abomasopexy
group and 60 of 60 (100%) cows in the omentopexy
TABLE 3. Item 15 example: Baseline characteristics of treatment cohorts in a randomized field trial comparing an autogenous vaccine to
a placebo vaccine on three university-owned beef cattle farmsa
Variable
Iowa State University
University of Wisconsin
Farm #1 Farm #2
Vaccinated
(n ~ 105)
Unvaccinated
(n ~ 109)
Vaccinated
(n ~ 38)
Unvaccinated
(n ~ 37)
Vaccinated
(n ~ 38)
Unvaccinated
(n ~ 38)
Enrollment weight (kg)
(mean ¡ SD)
77 (¡19) 78 (¡17) 110 (¡18) 107.3 (¡20) 80 (¡14) 80 (¡13)
Parity (%)
1–3 55 (52.2) 65 (59.6) 22 (57.9) 26 (70.3) 12 (31.6) 12 (31.6)
.3 50 (47.8) 44 (40.4) 16 (42.1) 11 (29.7) 26 (68.4) 26 (68.4)
Sex (%)
Heifer 49 (46.6) 53 (48.6) 19 (50) 24 (64.9) 18 (47.4) 22 (57.9)
Bull 56 (53.4) 56 (51.4) 19 (50) 13 (35.1) 20 (52.6) 16 (42.1)
a Reprinted with permission from Elsevier (37, p. 4588).
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(control) group. In the 1 cow in which we were not able to
successfully complete the surgical procedure, extensive
adhesion of the abomasum to the left ventral abdominal
wall resulted from a perforating ulcer, and repositioning was
therefore not possible. That cow was euthanatized and the
diagnosis confirmed during necropsy. Thus, data for that
cow were excluded from further evaluation (97).
The analyses were conducted on 1367 pigs born alive that were
nursing 126 sows. The standard care study group involved 60
litters with 647 piglets born alive, while the maximal care
study group contained 66 litters with 720 piglets born alive.
One maximal care sow was removed from the analysis because
she was suspected of having clinical porcine reproductive and
respiratory syndrome virus (PRRS) because all of her pigs
were born weak and she was anorexic. Another sow in the
standard care group was removed due to savaging. All pigs
nursing these sows were removed from the study. In addition,
107 pigs died before reaching 16 d of age, and so could not be
included in the analysis of the 16-d BW (28).
In order to evaluate the measure of effect, univariable as
treated analysis (AT) and intention to treat (IT) was used
(34).
Explanation
The number of study units analyzed in each interven-
tion group for each outcome is critical for understanding the
internal validity of the study. This information allows the
reader to assess loss to follow-up and protocol deviations for
all outcomes, as Item 13 addressed only the primary
outcome. Presenting the number of participants for binary
outcomes is important, because the event frequency should
be taken into account when interpreting effect measures
such as the risk ratio.
Intention-to-treat analysis relates to the treatment of study
units that have completed the study; therefore, an outcome is
available. Intention-to-treat analysis means that study units are
maintained in their allocated group regardless of any protocol
deviations, and randomization is preserved. Protocol viola-
tions commonly occur when animal-caregivers deviate from
the protocol. For example, a caregiver may decide to add an
additional antibiotic if they believe the animal is not
responding to the randomly assigned treatment. A protocol
violation may also occur if a poultry carcass is deemed eligible
for inclusion in a processing-level trial but is sent for re-
processing and thereby not available for sampling as part of
the regular processing system.
Intention-to-treat analysis represents the combined effect
of the application of the protocol as well as the protocol itself,
and may yield different results from analyses that only include
‘‘per protocol’’ study units. Inclusion of intention-to-treat and
per-protocol analyses is strongly recommended when assess-
ing protocols that involve changing management practices.
Different outcomes from intention-to-treat and per-protocol
analyses may suggest problems with the implementation of
the management practices rather than the actual practices. For
example, in a study on the impact of biosecurity practices on
disease rates on swine farms, some farms may not
conscientiously apply the biosecurity practices and violate
the assigned protocol. In this instance, and assuming that
biosecurity does reduce disease rates, the intention-to-treat
analysis would have a smaller treatment effect than the ‘‘per-
protocol’’ analysis. The difference between the two analyses
would have resulted from compliance issues rather than
biological efficacy of the biosecurity practice per se.
Understanding the nature of protocol violations may be
valuable to future research and recommendations. Intention-
to-treat analysis might suggest that the proposed protocol is
not effective; however, subsequent per-protocol analysis may
suggest that, when consistently applied, the practices are
efficacious. Such information is useful in designing further
producer programs.
The difference between per-protocol and intention-to-
treat analyses may not be applicable when the opportunity
for protocol violation is rare, as occurs with challenge
studies of short duration which involve a onetime
application of the intervention.
Item 17
For each primary and secondary outcome, a summary
of results for each group, accounting for each relevant level
of the organizational structure, and the estimated effect size
and its precision (e.g., 95% confidence interval).
Example
See Table 4.
Explanation
For each primary and secondary outcome reported in
Item 6, a summary outcome should be reported for each
TABLE 4. Item 17 example: Effect of tilmicosin (MIC) and
tulathromycin (DRAX) on feedlot performance of feedlot heifer
calves at moderate risk for bovine respiratory diseasea
Experimental groupb
Performance variable
MIC DRAX SEM P valuec
No. of pens 10 10
No. of heifers 2,250 2,244
Processing weight (lb) 604 603 0.90 0.70
DOF at terminal implant 137 137 0.14 0.34
Terminal implant weight (lb) 1,015 1,024 2.48 0.03*
DDMI at implant (lb) 18.7 19.2 0.14 0.03*
ADG at implant (lb/day) 3.02 3.09 0.2 0.03*
DMC at implant (lb/lb) 6.57 6.50 0.06 0.38
DOF at harvest 218 218 1.0
Final weight z (lb) 1,243 1,244 2.35 0.86
Final weight 2 (lb) 1,246 1,246 2.38 0.99
Final DDMI (lb) 20.0 20.3 0.18 0.28
Final ADG z (lb/day) 2.92 2.9 0.008 0.28
Final ADG 2 (lb/day) 2.87 2.87 0.009 0.99
Final DMC z (lb/lb) 6.87 6.95 0.06 0.32
Final DMC 2 (lb/lb) 6.97 7.02 0.05 0.49
a Reprinted with permission (109, p. 293). Copyright 2008
Veterinary Learning Systems, Yardley, PA.
b DOF, days on feed; DDMI, daily dry matter intake; ADG,
average daily gain; DMC, dry matter conversion; z, weight of
dead animals added; 2, weight of dead animals removed.
c Statistically significant differences (P # 0.05) are indicated with
an asterisk.
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intervention group. The rationale for providing this infor-
mation is to allow the reader to assess the clinical relevance
as well as the statistical significance of the differences
between the interventions groups, information that is better
conveyed by summary effect measures rather than by the
sole use of P values. Further, as meta-analyses and stochastic
modeling are sometimes conducted several years after
primary studies are reported, it is also advisable to provide
raw summary data for all relevant subpopulations.
For continuous outcomes, the mean and standard
deviation should be reported with the number in each
group, rather than reporting the mean difference. When
reporting proportions from binary data, include the absolute
numbers as well as the percentage or proportion (10/20
combined with 50% or 0.5).
A contrast measure (‘‘effect measure’’) between the
groups also should be included. For binary outcomes, this
may be the rate ratio, risk ratio, odds ratio, rate difference, or
risk difference. For survival data, the most commonly used
effect measure is the hazard ratio. For continuous data, the
effect measure generally is the differences in means among
intervention groups. For each effect measure, the 95%
confidence interval should be reported. If authors wish to
include the P value, it should be in addition to, not a
substitute for, the 95% confidence interval. Confidence
intervals convey considerably more information than
P values and are preferred (42).
It should be clear whether the effect measure was
unadjusted (i.e., a bivariable comparison between the
intervention groups) or whether it was adjusted for confound-
ing variables (not encouraged), non-independence, or both.
Given the impact of the extent of the intracluster correlation
on the power of the study, the intracluster correlation
coefficient or k statistic for each outcome should also be
provided (30). When interaction is present, effect measures for
each level of the interacting variable should be reported.
Results should be reported for all planned analyses,
including those that did not find a statistically significant
association between the intervention and the outcome. If the
study was conducted at multiple sites, site-specific summary
information should be provided as well as overall summary
information. This will allow readers to assess variation in
the effect measure across sites.
It is not recommended to report the parameter estimates
for logistic or Poisson models, as it is unnecessary work for
the reader to convert the parameter estimate to an effect
measure. In addition, it may not be possible to calculate the
effect measure if the authors failed to specify whether a
deviation from the mean versus reference coding was used
in the modeling described under Item 12.
Item 18
Address multiplicity by reporting any other analyses
performed, including subgroup analyses and adjusted analy-
ses, indicating those pre-specified and those exploratory.
Example
The rate of bacterial cures did not differ (P ~ .61) between
oxytocin-treated and antibiotic-treated cows (Table 3 [in
original citation]). Clinical cure rates were nearly identical (P
~ .99) for the three treatment groups. Treatment did not
significantly influence clinical or bacterial cure rate when the
data were stratified by herd (P ~ .27) (Table 3). When the
data were stratified by organism isolated, bacterial cure rate
did not differ by treatment (Table 4 [in original citation]).
Clinical cure rate did not differ by treatment, except that
treatment with either antibiotic improved clinical cure rate (P
~ .02) for the category of other bacteria (Table 4) (45).
Explanation
As the number of analyses using the same data
increases, so does the risk of false-positive findings (107).
Examples of multiple analyses include evaluating the
intervention against multiple outcomes; performing multiple
analyses based on control of different potential confounding
variables or within levels of an interaction variable; and
subgroup analysis, wherein interventions are evaluated
within a subgroup of study units on the basis of an
important characteristic (e.g., age group). Multiple out-
comes commonly are used in published trials. An evaluation
of 100 livestock health-and-production trials and 100 pre-
harvest food-safety trials reported a mean number of
outcomes per trial of 9.5 (range, 1–41) and 8.5 (range, 1–
51), respectively (89, 91). In trials with large numbers of
outcomes, the risk of a type I error is substantial, and
significant associations may be over interpreted. Studies
with multiple outcomes and/or subgroup analyses also have
a high risk of a type II error, as the power of the study is
usually calculated for the primary comparison and not for
additional analyses.
As discussed, subgroup analysis may be planned and
described a priori (preferred) or may be included as a post
hoc decision on the basis of preliminary analyses. If the
latter, the post hoc nature of the decision should be clearly
stated, and the results of the subgroup analysis should be
described as exploratory. Experience from human health
care suggests that authors should resist the temptation to
perform post hoc subgroup analyses (7, 12, 56, 80, 114).
Analyses that were pre-specified in the trial protocol are
much more reliable than those suggested by the data.
Authors should already have indicated which analyses were
pre-specified in Items 2, 5, 6, and 12.
When subgroup or adjusted analyses are performed,
information should already have been provided on the
specific subgroups that were analyzed and the reasons for
such analyses (see Item 12). All subgroup analyses that were
performed should be reported, regardless of the results; bias
may result from selective reporting of subgroup analyses.
Results from any formal tests of interaction (Item 12b)
should be provided in terms of estimated differences in the
intervention effect in each subgroup, including a confidence
interval, rather than only a P-value. A recent study reported
that 59 of 97 trials involved subgroup analyses, but only
46% reported interaction tests for some or all subgroup
analyses (111). Another study, involving 63 RCTs, found
that only 11 of 39 RCTs with subgroups included tests of
interaction (46). Additionally, details on analyses and
justifications for analyses should be provided whenever
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adjustments are made for baseline variables. If the study
included such adjustments, authors should specify whether
the adjustments and selection of adjusted variable(s) were
planned. Both unadjusted and adjusted result should also be
provided.
Item 19
All important adverse events or side effects in each
intervention group.
Examples
Postsurgical complications were observed in 7 (11.6%) cows
of the abomasopexy group, which did not differ significantly
(P~ 0.163; Fisher exact test [2- sided]) from the number of
cows with postsurgical complications (2 [3.3%]) in the
control group. Two cows in the abomasopexy group
developed moderate localized peritonitis that was more
severe than expected after the surgical procedure. Peritonitis
was diagnosed on the basis of clinical signs (fever, tenseness
of the abdominal wall, and moderate decrease in general
condition) and results of transabdominal ultrasonography.
Furthermore, 3 cows developed cellulitis at the abomasopexy
site, which was recognizable as a phlegmonous swelling of
the abdominal wall, and 2 cows had a relapse of the LDA
after they had kicked the gauze bandage off. For both cows
with relapse, a second laparoscopy-assisted abomasopexy
was successfully performed. None of the cows in the control
group had relapse of the LDA, but 2 cows developed a
purulent infection at the omentopexy site. All wound
infections (3 cows with cellulitis in the abomasopexy group
and 2 cows with purulent infection in the control group)
resolved after parenteral administration of an antimicrobial
for several days (97).
Two hundred and sixty-six animals were allocated to the LA
30 group, 265 animals were allocated to the LA 20 group,
and 266 animals were allocated to the FLOR group. There
were no adverse reactions in any of the experimental groups
(96).
Explanation
Many interventions have unintended and often unde-
sirable effects in addition to intended effects. Readers need
information about the harms as well as the benefits of
interventions to make rational and balanced decisions. The
existence and nature of adverse effects can have a major
impact on whether a particular intervention will be deemed
acceptable and useful. In livestock studies, adverse
reactions would include any occurrence that may affect
animal health, appearance, or performance. Further, an
adverse event may include reduced meat quality or safety.
For example, studies of management practices during
transportation may observe negative impacts on the carcass
grade or increased condemnations, and such adverse events
should be reported.
Not all reported adverse events observed during a trial
are necessarily a consequence of the intervention; some
may be a consequence of the condition being treated.
Randomized controlled trials offer the best approach for
providing safety data as well as efficacy data, although
they cannot be relied upon to detect rare adverse effects. At
a minimum, authors should provide estimates of the
frequency of the main severe adverse events and reasons
for treatment discontinuation separately for each interven-
tion group. If animals experience an adverse event more
than once, the data presented should refer to numbers of
affected animals; numbers of adverse events may also be of
interest.
Discussion
Item 20
Interpretation of the results, taking into account study
hypotheses, sources of potential bias or imprecision, and the
dangers associated with multiplicity of analyses and
outcomes. Where relevant, a discussion of herd immunity
should be included. If applicable, a discussion of the
relevance of the disease challenge should be included.
Example
The logistics of conducting research with privately owned
cattle meant that we often did not know when or where pens
of cattle were marketed, or we were unable to be at the site of
harvest; therefore, pens of cattle were enrolled by conve-
nience. We do not believe that this practice introduced
selection bias because pens of cattle were randomly assigned
to vaccine treatment initially and because research personnel
were blind to laboratory results when enrolling pens for the
current study. We found no evidence of selection bias based
on comparing the number of cattle per pen and the number of
days elapsing between arrival processing and reprocessing in
this study and the larger longitudinal study from which these
pens were enrolled (100).
Explanation
To encourage consistent format with the CONSORT
statement, the authors of the REFLECT statement agree
with the recommendation of the CONSORT Explanation
and Elaboration document, which proposes that authors
follow the five recommendations presented in the Annals of
Internal Medicine (64): (1) brief synopsis of the key
findings; (2) consideration of possible mechanisms and
explanations; (3) comparison with relevant findings from
other published studies (whenever possible including a
systematic review combining the results of the current study
with the results of all previous relevant studies); (4)
limitations of the present study (and methods used to
minimize and compensate for those limitations); and (5) a
brief section that summarizes the clinical and research
implications of the work, as appropriate.
Most, if not all, trials will have some limitations.
Therefore, the discussion section should include a discus-
sion of these limitations and the possible implications they
might have on the conclusions from the trial. The discussion
of study limitations should include any potential biases,
including the presence of uncontrolled confounding factors
or differences among intervention groups (16), or the
potential for selection bias. If possible, the impact of these
potential biases should be quantified. Sensitivity analyses
that illustrate the magnitude of confounding, misclassifica-
tion, or selection, that would be required to change the
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inference of the study, are preferable to statements such as
‘‘results should be interpreted with caution because of the
potential for confounding/misinformation/selection bias.’’ If
employed, these sensitivity analyses should be described in
the methods and materials and the results sections.
If blinding or formal randomization to treatment group
were not used, a discussion of the implications and objectivity
of the outcome (for non-blinded studies) should be included.
Authors should also discuss the number of subjects per
intervention group that did not complete the study and how
this may have affected the results and conclusions.
A consideration of potential imprecision in the outcome
measure also may be appropriate. Imprecision may be
introduced into a study at a number of points, such as when
the primary outcome is measured (Item 6) or during the
determination of whether a study units meets the eligibility
criteria (Item 3a). For instance, a blood test may have been
validated in adult cows, but not in calves, or a laboratory
technician may not be familiar with how to interpret a blood
smear from a particular species. Since this kind of issue has
the potential to increase imprecision, mention of such issues
should be made in the discussion.
Authors should address the biological and practical
importance of the work done, while not extrapolating the
results of their studies beyond the limits of their data. If the
trial included the evaluation of multiple outcomes, the
potential for type I errors should be discussed. Conversely,
if no significant associations with the intervention were
observed, authors should not interpret this as evidence of the
truth of the null hypothesis. In particular, failure to reject the
null hypothesis in a superiority study should not be
interpreted as evidence of equivalence (see Item 6) (51).
The statistical power of the trial should already be clear
from the methods and materials.
When appropriate, authors should also discuss the
potential effects of herd immunity, given the study design
chosen, i.e., individual or clustered allocation. An example of
the possible effects of herd immunity would be the evaluation
of vaccine efficacy. If a vaccine is efficacious, then one would
expect the control (non-vaccinated) group to also receive
some benefit due to interruption of disease transmission, if
they are in contact with the vaccinates. Therefore, when
animals within groups are allocated to vaccine, or when
groups within a common housing area are allocated to
vaccine, vaccine efficacy theoretically measures only the
direct benefits of vaccination and is likely an underestimate of
true vaccine efficacy. Thus, the choice of control group and
the implications of that choice in terms of possible herd
immunity should be discussed when applicable.
When challenge models are used, the discussion should
include a consideration of the degree to which the pathogen
represents wild-type pathogens, and the dose and route of
administration used in the study should be compared to the
dose and route of infection occurring in a natural disease
challenge.
Item 21
Generalizability (external validity) of the trial findings.
Examples
Although extrapolation of results obtained in experimentally
infected pigs to the field situation should be done with caution,
the infection model used allows studying the effects of
infections with M. [Mycoplasma] hyopneumoniae of different
virulence in a standardized and reproducible way (110).
The external validity of the study may have been
compromised to some extent because of the close proximity
of the experimental population to the regional agricultural
college (103).
Explanation
The external validity of a study refers to the degree to
which the study results can be generalized beyond the study
population (86). External validity may vary, depending on
the application for which the reader of the trial is
considering using the intervention. Factors involved in
determining external validity include the characteristics of
the study units and study population, the trial setting, and
the interventions and the outcomes measured (86). For
instance, there are often differences in the housing and
management of young stock, compared to mature animals or
animals in the finishing production stages. In ruminant
animals, trials conducted in pre-weaned animals may not be
relevant to post-weaned animals due to differences in
nutritional physiology. Therefore, when relevant, possible
limitations with extending the results of a trial to animals in
different production stages should be discussed. To allow
the reader to assess external validity, trial reports should
include sufficient information on (1) eligibility criteria (Item
3), (2) trial setting and location (Item 3), (3) interventions
and administration methods (Item 4), (4) outcome defini-
tions (Item 6), and (5) the recruitment and follow-up periods
(Item 14). However, the authors should also provide their
own interpretation of the external validity of the results.
Of particular relevance to livestock production is the
applicability of challenge trials. There may be substantive
differences between natural and artificial disease challenges,
including potential differences in the exposure dose, the
strain(s) used, and the route of administration. Challenge
studies also may use design features such as restriction of
the population and the study setting to reduce the potential
for confounding to bias the outcome. However, when
challenge trials are conducted in narrowly selected popula-
tions of animals, the study population may not represent the
target population (e.g., on the basis of age or weight, or
whether they are free of other important pathogens that
might be encountered under commercial conditions).
Challenge trials often are conducted in animals housed
individually or in small groups in laboratory settings, which
may not be representative of the environment that the target
population experiences. Thus, while challenge trials may
provide strong preliminary evidence of treatment efficacy,
their external validity will be not as strong as that of an RCT
conducted under commercial conditions.
Trials conducted in research herds also may use
different pen sizes or animal densities, compared to
commercial settings, and this will impact external validity.
Similarly, RCTs conducted at a single commercial site may
J. Food Prot., Vol. 73, No. 3 REFLECT STATEMENT 599
not be representative of the variety of settings possible, and
the authors should acknowledge this.
In addition, information on product safety, product
quality, and welfare of study subjects may be useful to
readers to decide on the applicability of results.
Item 22
General interpretation of the results in the context of
current evidence.
Example
In the present study, we evaluated the possible efficacy of
single cow calving pens for preventing neonatal calf diseases.
Utilizing single cow calving pens that are cleaned between
uses did not provide added protection to calves against calf
diseases. Husbandry practices other than maternity pen
management could have been relatively more important
determinants of preweaning health than use of single cow
calving pens. While it might be true that there really is little to
no added protection provided by single cow calving pens
against neonatal calf diseases, cautious interpretation of the
current results is in order due to lack of corroborative data
since no studies had previously attempted to address similar
questions using the study design employed in the present
study. These findings are inconclusive (82).
Explanation
When discussing the results of the study, the researcher
should consider and include the broader impacts of the results
relative to issues including, but not limited to, policy, societal
welfare and concern, and industry and stakeholder concern. At
a minimum, authors should discuss results of the study in the
context of all previous work whether the results are supportive
or not. If authors used a Bayesian analysis, it is recommended
that the description include estimates in terms of the results
from previous studies. If similar studies do not exist or are not
available for review, the authors should indicate this as a
limitation to their results. By placing the results in the context
of prior research, authors allow readers to interpret the results
of available studies relative to chronological changes in
animal populations (e.g., herd sizes, management practices),
disease processes, and interventions. Authors should avoid
including post hoc statements about the cost-benefit or cost
effectiveness of the intervention unless that was a stated
purpose of the manuscript and the methods for such analyses
were described in Items 6 and 12.
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